SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
0.825
+0.025 (3.07%)
Mar 9, 2026, 1:56 PM EDT - Market open
SCYNEXIS Employees
SCYNEXIS had 28 employees as of December 31, 2024. The number of employees decreased by 1 or -3.45% compared to the previous year.
Employees
28
Change (1Y)
-1
Growth (1Y)
-3.45%
Revenue / Employee
$735,750
Profits / Employee
-$307,464
Market Cap
34.60M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| InterCure | 320 |
| Zhengye Biotechnology Holding | 277 |
| Rockwell Medical | 244 |
| Cumberland Pharmaceuticals | 91 |
| Aytu BioPharma | 83 |
| Assertio Holdings | 58 |
| BioXcel Therapeutics | 37 |
| Talphera | 13 |
SCYX News
- 4 days ago - SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 11 days ago - SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247 - GlobeNewsWire
- 20 days ago - CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors - GlobeNewsWire
- 2 months ago - SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - GlobeNewsWire
- 3 months ago - SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK - GlobeNewsWire
- 4 months ago - SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study - GlobeNewsWire
- 6 months ago - SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12) - GlobeNewsWire